TY - JOUR
T1 - Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction
T2 - A literature systematic review
AU - Barbieri, Michelangela
AU - Chiodini, Paolo
AU - Di Gennaro, Piergiacomo
AU - Hafez, Gaye
AU - Liabeuf, Sophie
AU - Malyszko, Jolanta
AU - Mani, Laila-Yasmin
AU - Mattace-Raso, Francesco
AU - Pepin, Marion
AU - Perico, Norberto
AU - Simeoni, Mariadelina
AU - Zoccali, Carmine
AU - Tortorella, Giovanni
AU - Capuano, Annalisa
AU - Remuzzi, Giuseppe
AU - Capasso, Giovambattista
AU - Paolisso, Giuseppe
AU - Mayer, Christopher Clemens
N1 - Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2024/5
Y1 - 2024/5
N2 - Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.Graphical Abstract: see https://ars.els-cdn.com/content/image/1-s2.0-S1043661824000902-ga1.jpg
AB - Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.Graphical Abstract: see https://ars.els-cdn.com/content/image/1-s2.0-S1043661824000902-ga1.jpg
KW - Humans
KW - Erythropoietin/therapeutic use
KW - Neuroprotective Agents/therapeutic use
KW - Renal Insufficiency, Chronic/drug therapy
KW - Cognitive Dysfunction/drug therapy
KW - Animals
KW - Recombinant Proteins/therapeutic use
KW - Brain/drug effects
KW - Cognition/drug effects
U2 - 10.1016/j.phrs.2024.107146
DO - 10.1016/j.phrs.2024.107146
M3 - Article
C2 - 38493928
SN - 1043-6618
VL - 203
SP - 1
EP - 12
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 107146
ER -
